As the FDA begins lifting hormone therapy warnings, Longevitix argues the next gap is a clinical system designed around the whole woman.
For more than two decades, menopausal hormone therapy carried the most prominent safety warning the FDA can print. In February, the agency began taking parts of it off.
On 12 February, the FDA approved label changes for six products, removing risk statements on cardiovascular disease, breast cancer and probable dementia from the boxed warning, with 29 companies submitting revisions at the agency’s request [1]. The FDA puts the scale of the gap at about 41 million US women aged 45–64 in 2020, against about 2 million women aged 46–65 who received a hormone therapy prescription [1]. The endometrial cancer warning stays on systemic estrogen-alone products for women with a uterus [2]. The boxed warning traces to the Women’s Health Initiative findings [2]; the reversal has its critics, including Public Citizen’s Health Research Group, which objected to both the decision and the process [3].
Permission, then, is arriving. Infrastructure is another matter. Longevitix, a physician-led clinical intelligence platform for preventive and longevity medicine, argues that women’s health has never had any: a clinical system built around a woman’s whole physiology across her life, not a string of referrals.
Longevity.Technology: Medicine has a long habit of studying men and extrapolating to women, then building a specialty for whatever failed to extrapolate. The label change corrects one error in that story; it does not redraw the map. A woman at midlife can still find herself passed between a GP, a gynecologist, a cardiologist and a sleep clinic, each holding one page of a long document. Longevitix’s wager is that the page numbers matter – that life stage and sex belong in the clinical engine as context, not as a module bolted on at the end. It is a testable wager, and a more interesting one than another front door. The test is whether a physician, shown the whole timeline at once, decides differently. Software can supply the timeline. Reading it remains a human job.
Smaller men and the data they left behind
The gap has a paper trail. The FDA’s 1977 guidance advised keeping women of childbearing potential out of early-phase drug trials, and the agency did not revise that policy until 1993 [4]. NIH’s requirement that grant applicants account for sex as a biological variable took effect only in January 2016 [5]. Pharmacology kept the receipts: in a 2020 review of 86 drugs, 76 reached higher levels in women, and where adverse reactions could be identified (59 drugs), that gap predicted which sex got more of them 88% of the time [6]. Sometimes the correction arrives late and in plain sight. In 2013, the FDA halved the recommended zolpidem dose for women, who eliminate the drug more slowly than men [7].
Permission without preparation
Restoring the evidence is one thing; restoring the clinicians is slower. In a 2019 survey of 177 residents across family medicine, internal medicine, and obstetrics and gynecology, only 6.8% felt adequately prepared to manage menopause, and 20.3% reported no menopause lectures at all [8]. It was a small survey, with a 26% response rate, but an uncomfortable one. A label change tells clinicians what they may now say. It does not tell them what to check first.
Menopause sends its invoices elsewhere
Menopause arrives in the gynecologist’s diary and sends its invoices to everyone else. In the SWAN cohort, anti-Müllerian hormone levels in women aged 42 and over who were not yet postmenopausal could indicate bone loss under way or about to begin [9]. In a three-year imaging study of 59 adults aged 40 to 60, women in perimenopause and menopause showed faster declines in brain glucose metabolism than men, a pattern the authors described as female-specific [10]. Both studies are observational, and the imaging study is small, so neither proves that one intervention fixes everything. The shared lesson is that the signal can surface in a different organ system from the one the patient came in about.
What Longevitix says it does about it
Longevitix argues that the tools women do have – telehealth that prescribes, records that document the visit, trackers that log the cycle – each hold one piece of the picture, and none holds the timeline.
Its answer is to number the pages. The platform’s 15 organ-system AI specialists analyze each patient across cardiovascular, metabolic, hormonal, cognitive, musculoskeletal and sleep health, among others, the body-wide view that menopause demands. The Medical Summary can be viewed through specialist lenses, so a cardiologist and a gynecologist looking at the same patient each see the data organized around their own questions, with a women’s health lens among them. A shared thread lets the team agree a plan before the patient sees it.
By the company’s account, life stage is designed to run through all of it: where a woman sits on her reproductive-aging trajectory is treated as clinical context from the first intake, and dosing and route-of-administration suggestions pass through a sex-aware lens. The menopausal transition is treated as a keystone event, its effects traced from bone to brain and the links shown to the clinician rather than buried in a score.
“Women’s health shouldn’t be a module bolted onto the side of a clinical system,” Dr Neil Panchal, CMO and cofounder of Longevitix, told us. “Medicine spent decades extrapolating from male data, and a busy physician shouldn’t have to correct for that from memory. Life stage and sex need to shape every decision a physician makes, and the physician needs to stay in charge of each one.”
Every recommendation is traced to cited science, and nothing reaches the patient until a physician has reviewed and approved it.
Where the evidence runs thin
A platform can only reason from the evidence that exists, and for women that is thinner than it should be. That is the job of Longevitix’s five-tier evidence framework: a recommendation labeled emerging science should not wear the same badge as one backed by guidelines, and a physician should know which they are holding.
The FDA has rewritten the label. The chart is next.
Discover how Longevitix can support your clinic’s preventive care program and book a demo at https://longevitix.co/.
READ MORE: Building the infrastructure for preventive care
[1] https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
[2] https://www.fda.gov/drugs/drug-alerts-and-statements/fda-requests-labeling-changes-related-safety-information-clarify-benefitrisk-considerations
[3] https://citizen.org/article/outrage-of-the-month-labeling-changes-to-menopausal-hormone-therapy-products
[4] https://nap.nationalacademies.org/read/2343/chapter/2
[5] https://orwh.od.nih.gov/sex-as-biological-variable
[6] https://doi.org/10.1186/s13293-020-00308-5
[7] https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-new-label-changes-and-dosing-zolpidem-products-and
[8] https://doi.org/10.1016/j.mayocp.2018.08.033
[9] https://doi.org/10.1002/jbmr.4525
[10] https://doi.org/10.1371/journal.pone.0207885
